In conclusion, our study provides strong evidence that blocking of the PD1/PDL-1 pathway is a promising effective immunotherapeutic strategy against VL that restores protective antigen-specific CD4+ and CD8+ type 1 responses without inducing autoimmunity or immunopathology. This evidence concerns the gene CD4 and Autoimmunity.